QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 why-is-hcw-biologics-stock-surging-102-overnight

HCW Biologics' stock jumped 102.72% to $6.73 after the company revealed the successful development of second-generation T-c...

 hcw-biologics-inc-awarded-patent-number-us-12398189-b2-for-methods-of-activating-regulatory-t-cells

eyJzdWIiOiJiNWI5OThjOS03NjVhLTQ2YjAtYTQ3Yy0zMjBiNzEyNjg4N2UiLCJ2ZXIiOiIxOGVhMGE1Mi0yNWE5LTQzZDktYWY3ZS1iMDIyNjg2OGIzYmIiLCJleHA...

 hcw-biologics-shares-soar-on-breakthrough-second-generation-cancer-immunotherapy

HCW Biologics Inc. (NASDAQ: HCWB) shares were up Monday after the company announced a breakthrough in developing second-generat...

 hcw-biologics-shares-surge-after-unveiling-next-gen-cancer-immunotherapy-platform

HCW Biologics shares jump after unveiling TRBC-based fusion therapy that enhances immune response and shows strong preclinical ...

 hcw-biologics-announces-breakthrough-in-second-generation-pembrolizumab-based-immunotherapy-for-solid-tumors-showing-enhanced-immune-activation-and-tumor-infiltration

Company's pembrolizumab-based immune checkpoint inhibitor exhibited success against solid tumors in IND-enabling studies by...

 hcw-biologics-q2-eps-679-misses-180-estimate-sales-6550k-miss-7000m-estimate

HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(6.79) per share which missed the analyst consensus estimate of $1.80...

 hcw-biologics-says-payment-date-extended-for-license-fee-wy-biotech-to-confirm-wiring-of-7m-on-or-before-sept-30

-SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION